ReShape Lifesciences (RSLS) Competitors

Abbott Laboratories (NYSE:ABT) and ReShape Lifesciences (NASDAQ:RSLS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Do insiders and institutionals believe in ABT or RSLS?

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 0.0% of ReShape Lifesciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has higher valuation and earnings, ABT or RSLS?

Abbott Laboratories has higher revenue and earnings than ReShape Lifesciences. ReShape Lifesciences is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$42.34B	5.50	$13.40B	$7.71	17.36
ReShape Lifesciences	$8.01M	0.54	-$11.39M	-$343.02	-0.02

Does the media refer more to ABT or RSLS?

In the previous week, Abbott Laboratories had 41 more articles in the media than ReShape Lifesciences. MarketBeat recorded 43 mentions for Abbott Laboratories and 2 mentions for ReShape Lifesciences. Abbott Laboratories' average media sentiment score of 1.40 beat ReShape Lifesciences' score of 0.00 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	33 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ReShape Lifesciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in ABT or RSLS?

Abbott Laboratories received 554 more outperform votes than ReShape Lifesciences when rated by MarketBeat users. Likewise, 70.00% of users gave Abbott Laboratories an outperform vote while only 66.11% of users gave ReShape Lifesciences an outperform vote.

Company	Underperform	Outperform
Abbott Laboratories	Outperform Votes 952 70.00%	Underperform Votes 408 30.00%
ReShape Lifesciences	Outperform Votes 398 66.11%	Underperform Votes 204 33.89%

Which has more risk & volatility, ABT or RSLS?

Abbott Laboratories has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.

Do analysts recommend ABT or RSLS?

Abbott Laboratories currently has a consensus target price of $142.59, suggesting a potential upside of 6.55%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than ReShape Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.84
ReShape Lifesciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is ABT or RSLS more profitable?

Abbott Laboratories has a net margin of 31.95% compared to ReShape Lifesciences' net margin of -86.36%. Abbott Laboratories' return on equity of 20.74% beat ReShape Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	31.95%	20.74%	11.19%
ReShape Lifesciences	-86.36%	-179.83%	-91.48%

Summary

Abbott Laboratories beats ReShape Lifesciences on 18 of the 19 factors compared between the two stocks.